Xilio Therapeutics Files 8-K

Ticker: XLO · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1840233

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

Xilio filed an 8-K, but the key details are missing from this snippet.

AI Summary

Xilio Therapeutics, Inc. filed an 8-K on January 21, 2025, reporting on other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.

Why It Matters

This filing indicates that Xilio Therapeutics has made a regulatory submission, but the specific details of the events or financial information are not immediately clear from the provided text.

Risk Assessment

Risk Level: low — The filing is a standard 8-K, and the provided text lacks specific material information that would indicate a high risk.

Key Players & Entities

FAQ

What specific events are being reported in this 8-K filing?

The provided text indicates the filing is for 'Other Events' and 'Regulation FD Disclosure' but does not specify the nature of these events.

Are there any significant financial updates in this filing?

The filing mentions 'Financial Statements and Exhibits' but does not provide any specific financial figures or details in the text snippet.

What is the primary purpose of this 8-K filing for Xilio Therapeutics?

The filing serves as a Current Report for Xilio Therapeutics, Inc., detailing events that require public disclosure under SEC regulations.

When was this 8-K filing submitted?

The filing was submitted on January 21, 2025.

What is Xilio Therapeutics, Inc.'s principal executive office address?

Xilio Therapeutics, Inc.'s principal executive offices are located at 828 Winter Street, Suite 300, Waltham, Massachusetts 02451.

Filing Stats: 1,348 words · 5 min read · ~4 pages · Grade level 15.7 · Accepted 2025-01-21 17:09:06

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. From time to time, Xilio Therapeutics, Inc. (the "Company") presents or distributes slide presentations to the investment community to provide updates and summaries of its business. The Company is posting a copy of its current corporate investor presentation to the "Investors & Media" portion of its website at https://ir.xiliotx.com. The information contained on, or accessible through, the Company's website is not incorporated by reference into this Current Report on Form 8-K and should not be considered to be a part hereof. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

01. Other Events

Item 8.01. Other Events. On January 21, 2025, the Company issued a press release announcing initial data from its ongoing Phase 2 clinical trial evaluating vilastobart (XTX101) in combination with atezolizumab in patients with advanced solid tumors. These data will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2025 Gastrointestinal Cancer Symposium. The full text of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on, or accessible through, the websites referenced in the press release is not incorporated by reference into this Current Report on Form 8-K and should not be considered to be a part hereof. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, expectations and anticipated milestones for vilastobart (XTX101), including plans and timing for reporting Phase 2 clinical data for vilastobart in combination with atezolizumab in patients with microsatellite stable colorectal cancer; the potential benefits of vilastobart (as a monotherapy or combination therapy with a PD-(L)1 or other agent) or any of the Company's other current or future product candidates in treating patients as a monotherapy or combination therapy in any indication; the ultimate safety profile of vilastobart; and the Company's strategy, goals and anticipated financial performance, milestones, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "seek," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these ident

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate slide presentation of Xilio Therapeutics, Inc., dated January 21, 2025 99.2 Press release issued by Xilio Therapeutics, Inc. on January 21, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XILIO THERAPEUTICS, INC. Date: January 21, 2025 By: /s/ Christopher Frankenfield Christopher Frankenfield Chief Financial Officer and Chief Operating Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing